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Abstract
Background: Malaria and HIV are common causes of mortality in sub-Saharan Africa. The effect
of HIV infection on morbidity and mortality in children with severe malarial anaemia was assessed.
Methods: Children <5 years old were followed as part of a prospective cohort study to assess the
transfusion-associated  transmission of blood-borne pathogens at Mulago Hospital, Kampala,
Uganda. All children were hospitalized with a diagnosis of severe malarial anaemia requiring blood
transfusion. Survival to different time points post-transfusion was compared between HIV-infected
and uninfected children. Generalized estimating equations were used to analyse repeated
measurement outcomes of morbidity, adjusting for confounders.
Findings: Of 847 children, 78 (9.2%) were HIV-infected. Median follow-up time was 162 days
(inter-quartile range: 111, 169). HIV-infected children were more likely to die within 7 days (Hazard
ratio [HR] = 2.86, 95% Confidence interval [CI] 1.30–6.29, P = 0.009) and within 28 days (HR =
3.70, 95% CI 1.91–7.17, P < 0.001) of an episode of severe malarial anaemia, and were more likely
to die in the 6 months post-transfusion (HR = 5.70, 95% CI 3.54–9.16, P < 0.001) compared to HIV-
uninfected children. HIV-infected children had more frequent re-admissions due to malaria within
28 days (Incidence rate ratio (IRR) = 3.74, 95% CI 1.41–9.90, P = 0.008) and within 6 months (IRR
= 2.66, 95% CI 1.17 – 6.07, P = 0.02) post-transfusion than HIV-uninfected children.
Conclusion: HIV-infected children with severe malarial anaemia suffered higher all-cause mortality
and malaria-related mortality than HIV-uninfected children. Children with HIV and malaria should
receive aggressive treatment and further evaluation of their HIV disease, particularly with regard
to cotrimoxazole prophylaxis and antiretroviral therapy.
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Background
Malaria and human immunodeficiency virus (HIV) are
among the leading causes of death among children in sub-
Saharan Africa. In Uganda, malaria mortality among chil-
dren under 5 years is 37/1,000 person-years in areas of
high malaria endemicity and 18/1,000 person-years in
areas of low malaria endemicity [1,2] The prevalence of
HIV infection in Uganda is estimated at 7% in adults aged
15–49 years [3] and 1.7% in children under 5 years [4]. In
malaria-endemic areas, repeated childhood exposure to
episodes of malaria generates partial immunity, which
modifies the infection but does not fully prevent parasi-
taemia or clinical disease [5].
Because HIV infection interferes with cellular immune
function, HIV may interfere with the development of par-
tial immunity to malaria in children. Protection against
clinical malaria depends on cellular immunity, which
may be impaired in HIV-infected children with low CD4
lymphocyte counts[6]. Plasmodium falciparum malaria
lowers the CD4-CD8 ratio[7] and triggers the activation of
B cells, resulting in repeated activation of T4 lymphocytes
[8], a factor thought to contribute to the progression of
HIV disease [9]. Furthermore, chloroquine, the most com-
monly used treatment for malaria in East Africa at the time
of conducting the study, is itself an immunosuppressant
and interferes with antigen recognition by T cells, B cell
activation, and antibody production. HIV infection may
also impact a child's ability to respond to malaria treat-
ment [10,11].
Earlier studies failed to show an association between P.
falciparum malaria and HIV infection in children [10,12-
15]. However, these studies were limited by their cross-
sectional nature and shortcomings in diagnosing malaria.
Recent studies, including two prospective cohort studies,
have shown an association between HIV-associated
immuno-suppression and the severity of clinical malaria
in adults. [16-20]. One prospective cohort study showed
that malaria was more common among HIV-infected chil-
dren <5 years old than among HIV-uninfected chil-
dren[18], and a retrospective cohort study found higher
mortality among HIV-infected children with malaria
treated with chloroquine compared to HIV-uninfected
children[21]. A prospective cohort study of patients
receiving blood transfusions was conducted to examine
morbidity and mortality in HIV-infected and HIV-unin-
fected children with severe malarial anaemia requiring
transfusion.
Methods
Study design and subjects
This sub-study was part of a larger prospective cohort
study designed to assess the risk of transfusion-associated
infections among children and adults. For this analysis,
study participants included children (<5 years of age) hos-
pitalized with a diagnosis of malaria and requiring blood
transfusion between December 2000 and October 2001 at
Mulago Hospital in Kampala, Uganda. Mulago Hospital
serves as the primary referral hospital for Uganda. Study
staff identified potentially eligible subjects by reviewing
all physician requests for transfusion and approached
guardians or parents to determine eligibility and obtain
informed consent and assent. Admission due to malaria
was based on clinical criteria using sign/symptoms and
the availability of a hospital bed and blood units for trans-
fusion. Enrollment was offered immediately post-transfu-
sion at the ward; patients were eligible for enrollment if
their pre-transfusion blood specimen was available and
they were residing in the greater Kampala area. Patients
transfused in the six months preceding this current admis-
sion were not enrolled. Analysis was restricted to children
under five years of age transfused for severe malarial anae-
mia whose families consented to testing the child for HIV.
Investigators were not aware of the patients' HIV status,
but parents/legal guardians who consented to HIV testing
were counseled on their child's HIV status.
Most children were started on intravenous quinine at
enrollment and prescribed sulfadoxine-pyrimethamine
during follow-up. Quinine, artesunate and amodiaquine
were also prescribed during follow-up, based on the
child's clinical condition and anti-malarial treatment his-
tory. Patients received outpatient medical care at their fol-
low-up visits and were referred for re-admission if
warranted. The study protocol was reviewed and approved
by the Institutional Review Boards of the Centers for Dis-
ease Control and Prevention and the Uganda Virus
Research Institute, and approved by the Uganda National
Council for Science and Technology and the University of
California, Berkeley.
Measurements
HIV and haemoglobin-testing were conducted on the pre-
transfusion blood specimen obtained for blood typing
and cross-matching. Information on physical examina-
tion and medical history was abstracted from patient
medical records where available. Information was col-
lected on demographic characteristics, repeat-transfusions
during follow-up and common symptoms by interview-
ing the parent or guardian at the time of enrollment. Fol-
low-up was for between three and six months, with clinic
visits scheduled at weeks 1, 2, 4 and monthly thereafter.
Follow-up visits were at the patient's bed-side in the hos-
pital until discharge, and at the study clinic located in the
hospital thereafter. A physical examination was per-
formed at enrollment and at every other visit. An interval
medical history and a blood specimen were taken at every
visit. Blood smears for malaria were taken at scheduled
and unscheduled follow-up visits only if the child wasMalaria Journal 2007, 6:143 http://www.malariajournal.com/content/6/1/143
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febrile; thus, all follow-up cases of malaria were, by defi-
nition, symptomatic malaria episodes. All care was pro-
vided free of charge, and parents were encouraged to make
unscheduled clinic visits whenever their children were not
feeling well. So, in most cases, parents sought medical
help shortly after the time of symptom onset.
Severe anaemia was defined based on WHO adjusted cri-
teria [5] as a haemoglobin level less than 6.1 g/dl for chil-
dren less than 1 month old; less than 5.1 g/dl for children
ages 1 to less than 2 months; less than 4.4 g/dl for children
2 months to less than 3 months; less than 4.7 g/dl for chil-
dren 3 to less than 6 months; and less than 5.0 g/dl for
children 6 months to 5-years of age. To assess mortality,
field workers visited study participants' homes if they
failed to appear for a follow-up visit. In addition to vital
status, staff recorded reasons for loss to follow-up.
Laboratory methods
Pre-transfusion blood specimens were screened for HIV
by a single Enzyme Immunoassay (EIA) (Organon
Teknica, Durham, North Carolina, USA). Serum speci-
mens that were non-reactive on the first EIA were classi-
fied as HIV-negative; reactive specimens were retested in
duplicate with a different EIA (Sanofi-Genetic Systems,
Redmond, Washington, USA). If both repeat tests were
non-reactive, specimens were classified as HIV-negative. If
repeatedly reactive on the second EIA, specimens were
confirmed as HIV-positive using Western blot (Bio-RAD).
HIV infection status of children less than 24 months of
age was confirmed by RT-PCR. Malaria was diagnosed
using thick and thin smears and measured parasite density
semi-quantitatively as the number of parasitized cells per
200 white blood cells (WBC). All malaria slides were read
by two microscopists and, if the readings disagreed or for
quality control purposes, the slides were read by the
supervisor. The numbers of malaria parasites pre-transfu-
sion were scored as + for 1–20, ++ for 21–250, +++ for
251–500 and ++++ for 501 and greater. Malaria was
defined as reported fever and a thick smear indicating the
presence of plasmodia. Hyper-parasitaemia was defined
as the number of parasites per 200 WBC being greater
than 20% above the study population median[22]. An
episode of malaria was judged to be new if symptoms
began more than 4 weeks after a previous episode. Hae-
moglobin was measured using the Act 5 Diff instrument
(Beckman Coulter).
Statistical methods
Based on an estimated malaria incidence of approxi-
mately 2.5% per 6 months in the unexposed group, and a
type I error of 0.05, it was estimated that a cohort of 850
individuals would have 80% power to detect an incidence
rate ratio of 1.16 or a 16% increase in the malaria inci-
dence rate in the exposed group. Data were double-
entered using Epi-Info (CDC 2075A West Park Place,
Stone Mountain, GA 30087 USA) and analysed using
STATA (Stata Corporation, 702 University Drive East, Col-
lege Station, Texas 77840 USA).
Baseline differences were compared between HIV-infected
and HIV-uninfected children with respect to age, sex and
severity of malaria on admission. The likelihood of death
occurring within 7, 14, 21 and 28 days following a diag-
nosis of an episode of symptomatic malaria was evalu-
ated. Cox proportional hazards models were used to
compare mortality rates between HIV-infected and HIV-
uninfected children, with and without adjustment for
baseline differences in malaria treatment, age and sex. The
proportionality assumption was tested using log-log
plots, and generalized estimating equations (GEE) were
used to analyze repeated measurement outcomes of hos-
pital re-admission, new malaria episodes during follow-
up.
Results
Data were analysed from 847 children with a median age
of 1.2 years (inter-quartile range [IQR]: 0.7, 2.0). At
enrollment, HIV-infected children (n = 78, 9.2%) did not
differ from HIV-uninfected children (n = 769) with
respect to sex, age, pre-transfusion hyper-parasitaemia
and others markers of severity of malaria (Table 1). A total
of 803 children (95%) completed follow-up; 18 (2%)
were lost to follow-up, 13 (1.5%) moved before complet-
ing follow-up, and 13 (1.5%) refused further follow-up.
The median follow-up time was 162 days (IQR: 111–
169). The total follow-up time was 23.6 person-years for
the HIV-infected and 281.3 person-years for the HIV-
uninfected children.
Mortality
Vital status was determined at the last date of follow-up
for all 847 children. Seventy-six children (9.0%) died,
including 26 (33.3%) HIV-infected children and 50
(6.5%) HIV-uninfected children. Of the 76 deaths
recorded during follow-up, 45 (59%) occurred within 28
days of enrollment. During the 28 days following enroll-
ment, HIV-infected children were more likely to die than
HIV-uninfected children (hazard ratio (HR) 3.70 (95%CI
1.91–7.17; P < 0.001). The corresponding age, sex and
anti-malarial treatment adjusted hazard ratios of dying
within 7, 14, 21 days of a malaria episode between HIV-
infected children and HIV-uninfected children were 2.86
(95% CI 1.30–6.29, P = 0.009), 3.13 (95% CI 1.54–6.37,
P = 0.002) and 3.46 (95% CI 1.74–6.87, P < 0.001),
respectively.
During the six months following enrollment, the survival
probability was significantly worse among HIV-infected
children compared to HIV-uninfected children (log-rankMalaria Journal 2007, 6:143 http://www.malariajournal.com/content/6/1/143
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test for equality of survivor functions: χ2 = 65.9, p <
0.001). In the Cox proportional hazards analysis, HIV-
infected children with severe malarial anaemia had a sig-
nificantly higher rate of all-cause mortality (HR = 5.70,
95% CI 3.54 – 9.16, P < 0.001) and of death occurring
within 7, 14, 21 or 28 days of a symptomatic malaria diag-
nosis (HR 3.74 (95% CI 1.93 – 7.26, P < 0.001), 3.87
(95% CI 2.09 – 7.17, P < 0.001), 4.16 (95% CI 2.28 –
7.60, P < 0.001) or 4.88 (95% CI 2.83 – 8.42, P < 0.001),
respectively) when compared to HIV-uninfected children
(Table 2).
Though not statistically significant, high density malaria
episodes (hyper parasitaemia) were associated with an
increased risk of dying within 7 days of a symptomatic
malaria diagnosis. This risk of dying in children with high
density malaria episodes was approximately two times
that of children with low parasite density, HR = 1.62 (95%
CI 0.22 – 12.02, P = 0.64) for HIV-infected and HR = 2.25
(95% CI 0.90 – 5.61, P = 0.08) for HIV-uninfected chil-
dren.
Malaria infections and unscheduled clinic visits
P. falciparum was the only infecting malaria species in all
the samples tested. No difference was found in the inci-
dence of diagnosed malaria during visits in the six months
of follow-up between the HIV-infected and uninfected
children, even after restricting analysis to malaria episodes
that occurred more than 28 days apart (IRR 0.98, 95% CI
0.76 – 1.28). There was no difference in the incidence of
unscheduled clinic visits between HIV-infected and unin-
fected children (Table 2).
Morbidity: Re-admission following an initial episode of 
severe malarial anaemia
Thirty-six children (4%) were re-admitted to hospital
within four weeks following transfusion for malarial
anaemia, including 10 (13%) of the HIV-infected and 26
(3%) of the HIV-uninfected children. The risk of hospital
re-admission due to malaria within 28 days following a
first admission with severe malarial anaemia, adjusted for
differences in age and anti-malarial treatment received
before enrollment, was substantially elevated (IRR 3.74,
95% CI 1.41 – 9.90) in the HIV-infected children com-
pared to HIV-uninfected children. During the 6 months of
follow-up, re-admission due to malaria was also more
common (IRR 2.66, 95% CI 1.17 – 6.07) in HIV-infected
children than in HIV-uninfected children (Table 2).
Discussion
In children less than five years of age transfused for severe
malarial anaemia, restricting the analysis to 28 days after
enrollment, HIV-infected children were approximately
three times more likely to die within seven days of a symp-
tomatic malaria episode than HIV-uninfected children.
The increased risk of mortality remained, even after
adjusting for age, sex, malaria treatment regimen and clin-
ical signs of severe malarial anaemia at enrollment. The
mortality findings are consistent with longitudinal studies
in adults [23,24] and a retrospective study in children[21].
In another study conducted in Uganda [16], HIV-infected
children had more hospitalizations but showed no differ-
ence in the incidence of malaria episodes when compared
to HIV-uninfected children.
A causal relationship between HIV-infection and poor
response to malaria treatment is theoretically consistent
with what is known about HIV pathogenesis [7,8]. HIV-
infected children had similar rates of malaria episodes but
were hospitalized more often than HIV-uninfected chil-
dren. This finding suggests that HIV-infected children may
have an impaired immune response, impeding clearance
of malaria parasites and increasing the risk of complica-
tions that may require hospitalization.
A limitation of this study was the uncertainty as to
whether the excess deaths among the HIV-infected chil-
dren with severe malarial anaemia were due to malaria or
Table 1: Sex, age and markers of severity of malaria at enrollment among HIV-infected and HIV-uninfected children under 5 years, 
Kampala, Uganda
Baseline variables HIV- uninfected children (n = 769) HIV-infected children (n = 78) Total N = 847 P-value*
Sex (female) 356 46% 37 47% 393 46% 0.85
Age under 1 year 321 42% 30 38% 351 41% 0.58
Respiratory distress 287 37% 30 38% 317 37% 0.84
Jaundice 71 9% 6 8% 77 9% 0.64
Splenomegaly 388 52% 41 53% 429 52% 0.87
Hepatomegaly 160 21% 15 19% 175 21% 0.68
Post-transfusion severe anaemia+ 494 78% 51 80% 545 78% 0.78
Pre-transfusion hyper-parasitaemia 55 7% 6 8% 61 7% 0.82
Treatment with Quinine (I.V.) 584 76% 57 74% 641 76% 0.57
*Chi-square test for difference in proportions


























































































































Table 2: Morbidity and mortality among HIV-infected and HIV-uninfected children <5 years old with severe malarial anaemia
HIV infected children (N = 78) 
Years of follow-up = 5.2
HIV uninfected children (N = 769) 
Years of follow-up = 55.0
† Hazard ratio (HR) or Incidence 
rate ratio (IRR)
P-value
In the 28 days following first admission with severe 
malarial anaemia
Episodes or Deaths Rate per 100 person-years Episodes or Deaths Rate per 100 person-Years
Mortality
Death within 7 days of a malaria episode 8 153.8 28 50.9 2.86 (1.30 – 6.29) 0.009
Death within 28 days of a malaria episode 12 230.8 33 60.0 3.70 (1.91 – 7.17) <0.001
Hospital admissions
Any reason for re-admission 11 211.5 28 50.9 4.05 (1.95 – 8.43) <0.001
Re-admission due to malaria 5 96.2 13 23.6 3.74 (1.41 – 9.90) 0.008
In the 6 months follow-up (Includes repeat episodes)
Mortality
All cause mortality 26 110.2 50 17.8 5.70 (3.54 – 9.16) <0.001
Death within 7 days of any malaria episode 12 50.8 33 11.7 3.74 (1.93 – 7.26) <0.001
Death within 28 days of any malaria episode 19 80.5 41 14.6 4.88 (2.83 – 8.42) <0.001
Hospital admissions
Any reason for re-admission 18 76.3 66 23.5 2.93 (1.62 – 5.29) <0.001
Re-admissions due to malaria 7 29.7 26 9.2 2.66 (1.17 – 6.07) 0.02
Malaria incidence
Malaria diagnosed during visits after enrollment 92 394.1 881 313.9 1.12 (0.91 – 1.38) 0.273
Malaria episode >28 days after last malaria episode 54 228.8 582 206.9 0.98 (0.76 – 1.28) 0.895
Unscheduled visits
Unscheduled visits to the clinic 24 101.7 227 80.7 1.14 (0.74 – 1.77) 0.543
† Adjusted for age, sex and baseline quinine treatment statusMalaria Journal 2007, 6:143 http://www.malariajournal.com/content/6/1/143
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due to other competing causes related to HIV infection.
Without a post-mortem examination, it is difficult to
ascertain the cause of death and eliminate competing
causes of death due to other HIV associated co-morbidi-
ties. However, an association was found between HIV
infection and mortality even when the outcome measure
was restricted to deaths occurring within seven days of
diagnosis of severe malarial anaemia, making competing
illnesses a less likely explanation. Data on clinical staging
or CD4 count for HIV-infected children were not availa-
ble. CD4 cell count has previously been associated with
an increased risk of malaria infection [25], and a causal
relationship between HIV-related immunosuppression
and malaria-related mortality would be strengthened by
observing an effect between lower CD4 count and
increased mortality. Differences in anti-malaria treatment
received before admission and during follow-up might
have affected the risk of mortality; however, because 75%
of study participants were treated with quinine at baseline
and both HIV-infected and HIV-uninfected children were
treated using the same anti-malarial treatment protocol
during follow-up, it is unlikely that treatment differences
in this study significantly affected the final results. None
of the study participants was on antiretroviral therapy or
cotrimoxazole prophylaxis at the time of the study. With-
out data from blood and other cultures on treatments
such as antimicrobial therapy it was not possible to rule
out the possibility of co-existing bacteraemia, which is a
common cause of morbidity and mortality in children in
Uganda. Bias could also have been introduced if parents/
legal guardians counseled on their child's HIV status were
more likely to bring their children for health care during
follow-up and therefore leading to an increase in hospital
admissions. However, when hospital admission rates
were compared between HIV-infected children whose par-
ents/legal guardians knew their child's HIV status and
those who did not know their child's HIV status, no signif-
icant difference was observed [Data not shown]. Lastly,
the occurrence of haemoglobinopathies, in particular
Glucose 6-phosphate (G6P) dehydrogenase deficiency
may pre-dispose HIV-infected children to more recurrent
anaemia and therefore modify the effect of HIV on the
incidence of malaria.
The interaction between malaria and HIV-infection
among children has profound implications for child
health in Africa, given the high incidence of malaria and
the fact that more than 90% of the world's children with
HIV reside in Africa. Several interventions regarding
malaria may be beneficial for HIV-infected children living
in Africa. Cotrimoxazole prophylaxis has been associated
with a reduced incidence [26,27] of malaria and lower
mortality [26] among HIV-infected children, and is cur-
rently recommended by WHO[28]. Insecticide-treated
bed nets are associated with a 50% reduction in malaria
among children living in endemic areas[29], and are likely
to be equally effective for HIV-infected and uninfected
children. This study has demonstrated that children
infected with HIV and malaria have more severe malaria
disease outcomes and therefore should receive aggressive
treatment and further evaluation of their HIV disease out-
comes for a possibility of starting them on antiretroviral
therapy. Additionally, other basic interventions to prevent
malaria should be initiated in HIV-infected children. In
particular, consideration should be given to initiating cot-
rimoxazole prophylaxis while the HIV/AIDS disease status
is being determined and providing parental education
regarding febrile episodes in their HIV infected children.
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